Status
Conditions
About
This prospective study aims to investigate serum soluble B-cell maturation antigen (sBCMA) as a non-invasive marker in patients with multiple myeloma and to compare its levels with healthy controls.
Full description
Multiple myeloma is a malignant plasma cell disorder. Current monitoring relies on invasive bone marrow examination and monoclonal protein assays, which may be limited in oligosecretory disease.
This observational study will measure serum soluble BCMA levels in newly diagnosed and relapsed/refractory multiple myeloma patients and compare them with healthy controls. The relationship between sBCMA levels and clinical and laboratory disease characteristics will be assessed.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Group 2 (Relapsed/Refractory MM):
Group 3 (Controls):
Exclusion criteria
90 participants in 3 patient groups
Loading...
Central trial contact
Naira A Ezz, Resident
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal